Articles From: Dicerna Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma to SM Energy Announces Leadership Transition


2015/2/2
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi therapeutics, today announced that the first patient has been dosed in a global Phase 1b/2 clinical trial of DCR-MYC, an investigational Dicer substrate short interfering RNA (DsiRNA) therapeutic, in patients with advanced hepatocellular carcinoma (HCC). This new trial expands the development program for DCR-MYC, which is also being studied in a Phase 1 clinical trial in patients with solid tumors and hematological malignancies.
Sign-up for Dicerna Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma investment picks
2015/2/2
HARTSVILLE, S.C., Feb.
Sign-up for Sonoco Announces Price Increase for All Uncoated Recycled Paperboard Products investment picks
2015/2/2
HOUSTON, Feb.
Sign-up for Cardtronics Extends ATM Services Agreement With The Pantry investment picks
2015/2/2
CHARLOTTE, N.C., Feb.
Sign-up for Capitala Finance Corp. Completes $20.0 Million Investment in Tender Greens Holdings, LLC investment picks
2015/2/2
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced topline Phase 3 results from the GIFT-1 study, AbbVie’s investigational, all-oral, ribavirin-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan.
Sign-up for Enanta Announces 95 percent SVR12 rate in AbbVie’s Phase 3 Study of All-Oral Treatment for Hepatitis C Virus in Japanese Patients investment picks
2015/2/2
CAYCE, S.C. , Feb.
Sign-up for SCANA Announces the Closing of the Sale of Carolina Gas Transmission Corporation investment picks
2015/2/2
TEL AVIV, Israel, Feb.
Sign-up for Bio Blast Announces Key Leadership Changes investment picks
2015/2/2
RADNOR, Pa., Feb.
Sign-up for Marinus Pharmaceuticals to Present at BIO CEO & Investor Conference investment picks
2015/2/2
HOUSTON, TEXAS, Feb.
Sign-up for Halcon Announces Dividend Declaration on Series A Cumulative Perpetual Convertible Preferred Stock investment picks
2015/2/2
KANSAS CITY, Mo., Feb.
Sign-up for Cerner Completes Acquisition of Siemens Health Services investment picks
2015/2/2
By Sara Sjolin, MarketWatch LONDON (MarketWatch) -- After touching the highest levels since 2013, Greek borrowing costs moved firmly lower in midmorning trade on Monday as the country's prime minister Alexis Tsipras ruled out an exit from the eurozone.
Sign-up for UPDATE: Greek yields ease as Tsipras rules out 'Grexit' and Russian aid investment picks
2015/2/2
MARLBOROUGH, Mass.
Sign-up for RXi Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference investment picks
2015/2/2
NEW YORK , Feb.
Sign-up for iStar Financial Announces Tax Treatment of 2014 Dividends investment picks
2015/2/2
SHELTON, Conn., Feb.
Sign-up for Cara Therapeutics to Webcast Presentation at 17th Annual BIO CEO & Investor Conference investment picks
2015/2/2
Choice Properties Real Estate Investment Trust Completes Acquisition of Warehouse Property and Provides Update on Recent Property Transactions Canada NewsWire /NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES ./ TORONTO , Feb.
Sign-up for Choice Properties Real Estate Investment Trust Completes Acquisition of Warehouse Property and Provides Update on Recent Property Transactions investment picks
2015/2/2
ROCKVILLE, Md.
Sign-up for CASI Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference investment picks
2015/2/2
EWING, N.J. , Feb.
Sign-up for Celator® Pharmaceuticals to Present at BIO CEO and Investor Conference investment picks
2015/2/2
1-800-FLOWERS.COM, Inc. (NASDAQ:FLWS), the world’s leading florist and gift shop, today reported total net revenues from continuing operations of $534.3 million for its fiscal 2015 second quarter ended December 28, 2014, compared with revenues from continuing operations of $266.3 million in the prior year period.
Sign-up for 1-800-FLOWERS.COM, Inc. Reports Strong Results from Continuing Operations for Its Fiscal 2015 Second Quarter investment picks
2015/2/2
LifePoint Hospitals® (NASDAQ: LPNT), a leading hospital company focused on providing quality healthcare services close to home, and the Nason Hospital Board of Directors today announced that the acquisition of Nason Hospital by LifePoint has been completed.
Sign-up for Nason Hospital and LifePoint Hospitals Finalize Acquisition investment picks
2015/2/2
Big data analytics provider Sysorex (NASDAQ:SYRX) today announced it was awarded three new projects in the state of Washington with an aggregate value of approximately $1.3 million.
Sign-up for Sysorex Named One of the Largest Big Data Firms in Seattle Area; Announces $1.3 Million in New Pacific Northwest Projects investment picks
2015/2/2
Village Farms International, Inc. Completes Another Exclusive Seed Agreement Canada NewsWire TRADING SYMBOL: The Toronto Stock Exchange: Village Farms International, Inc. – VFF VANCOUVER , Feb.
Sign-up for Village Farms International, Inc. Completes Another Exclusive Seed Agreement investment picks
2015/2/2
Pompano Beach, Fla., Feb.
Sign-up for DS Healthcare to enter 320 locations at 18/8 Fine Men's Salon franchise investment picks
2015/2/2
Step out Drilling expands the strike length of the Marathon Zone with 2.02 g/t Au over 17.0 meters (TT) Valentine Gold Camp, Newfoundland Canada NewsWire TORONTO , Feb.
Sign-up for Step out Drilling expands the strike length of the Marathon Zone with 2.02 g/t Au over 17.0 meters (TT) Valentine Gold Camp, Newfoundland investment picks
2015/2/2
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Pratik S.
Sign-up for Ignyta Expands Clinical Leadership Team with Appointments of Pratik Multani, M.D., M.S., as Chief Medical Officer and Adrian Senderowicz, M.D., as Clinical and Regulatory Strategy Officer investment picks
2015/2/2
Centric Health Completes Reacquisition of Seniors Wellness and Home Care Operations Canada NewsWire TORONTO , Feb.
Sign-up for Centric Health Completes Reacquisition of Seniors Wellness and Home Care Operations investment picks
2015/2/2
TVI Appoints Shirley Anthony as VP Corporate Communications Canada NewsWire TSX: TVI OTCQX: TVIPF CALGARY , Feb, 2, 2015 /CNW/ - TVI Pacific Inc. (TSX: TVI) (OTCQX: TVIPF) ("TVI" or "the Company") is pleased to announce the appointment of Shirley Anthony to the position of Vice President of Corporate Communications, effective immediately.
Sign-up for TVI Appoints Shirley Anthony as VP Corporate Communications investment picks
2015/2/2
Salix Pharmaceuticals, Ltd.
Sign-up for Salix Announces the Promotion of William P. Forbes, PharmD to President, Medical, R&D and Chief Development Officer investment picks
2015/2/2
SM Energy Company (NYSE: SM) today announces that as part of its previously announced leadership transition plan, Anthony J.
Sign-up for SM Energy Announces Leadership Transition investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Dicerna Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma to SM Energy Announces Leadership Transition
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent